ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03468725
Recruitment Status : Completed
First Posted : March 16, 2018
Last Update Posted : September 18, 2018
Sponsor:
Information provided by (Responsible Party):
Xenon Pharmaceuticals Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The XEN1101 Phase 1 clinical trial is a randomized, double-blind, placebo-controlled study that will eventuate the safety, tolerability, pharmacokinetics (PK) and effects on transcranial magnetic stimulation (TMS) of oral doses of XEN1101 in healthy male subjects.The TMS procedure is designed to demonstrate delivery of XEN1101 into the central nervous system and to observe a change in cortical excitability as measured by EEG and/or EMG activity. It is estimated there will be approximately 15 subjects in the planned study.

Condition or disease Intervention/treatment Phase
Healthy Male Volunteers Drug: XPF-008 Drug: Microcrystalline Cellulose Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Placebo-controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Administration of XEN1101 in Healthy Male Subjects
Actual Study Start Date : February 13, 2018
Actual Primary Completion Date : July 31, 2018
Actual Study Completion Date : July 31, 2018
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: XPF-008
Single oral dose
 Drug: XPF-008
Capsule filled with XEN1101
Active Comparator: Placebo
Single oral dose
 Drug: Microcrystalline Cellulose
Placebo capsule


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of participants with adverse events (AEs) as assessed by CTCAE v4.03 [ Time Frame: From screening (28 days prior to Day 1) through to 30 days post-final dose ]
    To assess AEs as a criteria of safety and tolerability

  2. Resting 12-lead electrocardiogram (ECG) [ Time Frame: From screening (28 days prior to Day 1) through to Day 14 ]
    To assess ECG intervals (PR, QRS, QTcF, RR) as a criteria of safety and tolerability

  3. Number of participants with vital sign abnormalities [ Time Frame: From screening (28 days prior to Day 1) through to Day 14 ]
    To assess vital signs as a criteria of safety and tolerability

  4. Pharmacodynamic (PD) Effects assessed by Transcranial Magnetic Stimulation (TMS) biological markers of brain excitability [ Time Frame: Day 1 predose through to Day 7 ]
    To assess biological marker of brain excitability: amplitude (in uV) of TMS evoked potentials on the EEG

  5. PD Effects assessed by TMS biological markers of brain excitability [ Time Frame: Day 1 predose through to Day 7 ]
    To assess biological marker of brain excitability: resting motor threshold (in %) for elicitation of an electromyographic response


Secondary Outcome Measures :
  1. Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Day 1 predose through to Day 8 ]
    Cmax is the maximum observed plasma concentration in ng/mL

  2. Terminal elimination half-life (t1/2) [ Time Frame: Day 1 predose through to Day 8 ]
    The time in hours required for the plasma level of the study drug to decrease by one-half during the terminal elimination phase

  3. Area Under the Plasma Concentration-Time Curve from Time Zero to the Time of the Last Quantifiable Plasma Concentration (AUC0-last) [ Time Frame: Day 1 predose through to Day 8 ]
    The area under the plasma concentration-time curve [in ng.h/mL] from time zero to the time corresponding to the last quantifiable plasma concentration


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Key Inclusion Criteria:

  • Healthy male aged between 18 and 55 years inclusive with a body mass index (BMI) between 18.5 and 30.0 kg/m2
  • Right-handed only
  • Must agree to use effective methods of contraception, if applicable
  • Able to swallow multiple capsules
  • Able to provide written, personally signed and dated Informed Consent Form

Key Exclusion Criteria:

  • Any current and relevant history of significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk, affect clinical or laboratory results, or the subject's ability to participate in the study
  • Any clinically significant abnormalities in vital signs, ECGs, physical examinations, or laboratory evaluations
  • Answering "yes" to any of the questions within the Columbia Suicide Severity Rating Scale Mental incapacity or language barriers precluding adequate understanding, cooperation, and compliance with the study
  • No prescription or over-the-counter (OTC) medications (including multivitamins, herbal or homeopathic preparations 14 days or if applicable/available, 5 half-lives prior to dosing to study end
  • Any history of severe head trauma
  • No smoking 60 days prior to dosing to study end
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03468725


Locations
United Kingdom
King's College Hospital
Brixton, London, United Kingdom, SE5 9RS
Sponsors and Collaborators
Xenon Pharmaceuticals Inc.
Investigators
Study Director: Gregory Beatch, PhD Xenon Pharmaceuticals Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Xenon Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT03468725     History of Changes
Other Study ID Numbers: XPF-008-101b
2017-003181-27 ( EudraCT Number )
C17047 ( Other Identifier: Richmond Pharmacology's Study Code )
First Posted: March 16, 2018    Key Record Dates
Last Update Posted: September 18, 2018
Last Verified: September 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Xenon Pharmaceuticals Inc.:
Transcranial magnetic stimulation